0.94

1.02% 0.0095

Estrella Immunopharma Inc (ESLA)

Overview News Price History Discussions Forecast

Estrella Immunopharma Inc stock is traded at $0.94, with a volume of 18,891. It is up +1.02% in the last 24 hours and down -9.62% over the past month. Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Previous Close:

$0.9305

Open:

$0.897

24h Volume:

18,891

Relative Volume:

0.10

Market Cap:

$37.61M

Revenue:

Net Income/Loss:

$-8.53M

P/E Ratio:

-3.862

EPS:

-0.2434

Net Cash Flow:

$-12.75M

1W Performance:

+0.92%

1M Performance:

-9.62%

6M Performance:

-19.66%

1Y Performance:

+2.17%

1-Day Range:

$0.87

$0.9429

1-Week Range:

$0.87

$1.0036

52-Week Range:

$0.63

$3.23

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name

Estrella Immunopharma Inc

Sector

Healthcare (1170)

Industry

Biotechnology (661)

Phone

(510) 318-9098

Address

5858 HORTON STREET, SUITE 370, EMERYVILLE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ESLA's Discussions on Twitter

Compare ESLA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESLA Estrella Immunopharma Inc	0.94	37.61M	0	-8.53M	-12.75M	-0.2434
VRTX Vertex Pharmaceuticals Inc	443.40	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	521.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	318.25	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.04	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	254.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Estrella Immunopharma Inc Stock (ESLA) Latest News

Jun 07, 2025

Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN

Jun 07, 2025

Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa

Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener

Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace

Jun 05, 2025

Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus

Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia

Jun 05, 2025

Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks

Jun 05, 2025

Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com

Jun 05, 2025

Jun 04, 2025

Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN

Jun 04, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus

Jun 04, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa

Jun 04, 2025

Jun 03, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus

Jun 03, 2025

Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus

Jun 03, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia

Jun 03, 2025

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire

Jun 03, 2025

May 30, 2025

Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

May 30, 2025

May 29, 2025